Quantifying Knowledge of Alzheimer's Disease: An Analysis of the Psychometric Properties of the Alzheimer's Disease Knowledge Scale.

Alzheimer’s Disease Knowledge Scale Alzheimer’s disease Knowledge Psychometric assessment

Journal

Neurology and therapy
ISSN: 2193-8253
Titre abrégé: Neurol Ther
Pays: New Zealand
ID NLM: 101637818

Informations de publication

Date de publication:
Jun 2021
Historique:
received: 16 11 2020
accepted: 06 01 2021
pubmed: 30 1 2021
medline: 30 1 2021
entrez: 29 1 2021
Statut: ppublish

Résumé

The Alzheimer's Disease Knowledge Scale (ADKS) is one of the most popular instruments for assessing a person's knowledge regarding Alzheimer's disease (AD). The objective of this study was to explore ADKS item characteristics with item response theory (IRT) procedures. A noninterventional web-based study was conducted. A nonparametric IRT procedure, Mokken analysis, was used to explore the underlying latent structure of the ADKS and ADKS item characteristics regarding scalability and violations of the monotone homogeneity (MH) model. A random-effects meta-analysis was implemented that combined ADKS scores from independent studies. A total of 447 employees of a pharmaceutical company participated in the study. The mean ADKS score was 21.2 (SD 2.8). Mokken analysis showed that most ADKS items (22 of 30) do not fit to any scale and can be considered to be scale independent. Two items (#1: particularly prone to depression; #20: depression can be mistaken for AD) fit to a domain relating to depression, another two items (#2: mental exercise can prevent AD development; #8: benefit of psychotherapy) can be related to potential prevention and improvement, and four items (#12: poor nutrition can make the symptoms worse; #18: high cholesterol may increase the risk of AD; #26: high blood pressure may increase the risk of AD; #27: genes can only partially account for AD development) fit to a risk factor domain. As expected from those results, neither the overall scale (H = 0.033) nor its items showed appropriate scalability index values, suggesting that ADKS does not fit to a MH model. Eleven items showed violations of the assumptions of the MH model. The meta-analytical average score was 21.78 (95% CI 20.67-22.90), with healthcare professionals and caregivers showing the highest levels of AD knowledge. Although the ADKS does not present a unidimensional structure, its independent items together provide a comprehensive spectrum of information regarding AD knowledge.

Identifiants

pubmed: 33512697
doi: 10.1007/s40120-021-00230-x
pii: 10.1007/s40120-021-00230-x
pmc: PMC8139996
doi:

Types de publication

Journal Article

Langues

eng

Pagination

213-224

Références

Aging Ment Health. 2021 May;25(5):787-796
pubmed: 32048522
BMC Geriatr. 2019 Mar 4;19(1):63
pubmed: 30832618
Lancet Neurol. 2019 Jan;18(1):88-106
pubmed: 30497964
J Korean Acad Nurs. 2015 Feb;45(1):107-17
pubmed: 25743739
Gerontologist. 2009 Apr;49(2):236-47
pubmed: 19363018
Patient Prefer Adherence. 2020 Dec 01;14:2357-2364
pubmed: 33293798
Ageing Res Rev. 2012 Jan;11(1):67-77
pubmed: 21983429
Neurologia (Engl Ed). 2021 Jul-Aug;36(6):426-432
pubmed: 34238525
Dement Geriatr Cogn Dis Extra. 2019 Oct 1;9(3):352-361
pubmed: 31616459
Australas J Ageing. 2017 Mar;36(1):38-45
pubmed: 26970426
Int J Alzheimers Dis. 2020 Jan 9;2020:6173217
pubmed: 32494366
Aging Ment Health. 2012;16(4):521-8
pubmed: 22129312
Am J Alzheimers Dis Other Demen. 2015 Feb;30(1):98-100
pubmed: 25425736
BMC Fam Pract. 2020 May 16;21(1):89
pubmed: 32416731
Front Pharmacol. 2019 Aug 14;10:860
pubmed: 31474852
Alzheimer Dis Assoc Disord. 2015 Jul-Sep;29(3):255-75
pubmed: 26207322
Adv Neurobiol. 2017;15:31-53
pubmed: 28674977
J Am Geriatr Soc. 2016 Jun;64(6):1329-34
pubmed: 27321614
Arq Neuropsiquiatr. 2018 Nov;76(11):775-782
pubmed: 30570022
BMC Geriatr. 2013 Jan 02;13:2
pubmed: 23282030
Front Pharmacol. 2017 Oct 26;8:739
pubmed: 29123479
J Med Internet Res. 2015 Oct 30;17(10):e241
pubmed: 26519106
Br J Math Stat Psychol. 2017 Feb;70(1):137-158
pubmed: 27958642

Auteurs

Guillermo Garcia-Ribas (G)

Department of Neurology, Hospital Universitario Ramón Y Cajal, Madrid, Spain.

Elena García-Arcelay (E)

Medical Department, Roche Farma, Madrid, Spain. elena.garcia_arcelay.eg1@roche.com.

Alonso Montoya (A)

Medical Affairs, Neuroscience, Hoffmann-La Roche Limited, Mississauga, ON, Canada.

Jorge Maurino (J)

Medical Department, Roche Farma, Madrid, Spain.

Javier Ballesteros (J)

Department of Neurosciences and CIBERSAM, University of the Basque Country, Leioa, Spain.

Classifications MeSH